No Data
No Data
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Immatics (NASDAQ:IMTX) Shareholders Are Still up 47% Over 1 Year Despite Pulling Back 7.9% in the Past Week
Immatics N.V. (NASDAQ:IMTX) shareholders have seen the share price descend 10% over the month. While that might be a setback, it doesn't negate the nice returns received over the last twelve months
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Express News | Immatics Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q4 Financial Results
Sector Update: Health Care Stocks Gain Pre-Bell Thursday
Health care stocks were gaining pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was up 0.7% recently. Immatics (IMTX) shares
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
No Data